Year 2008,
Volume: 21 Issue: 1, 11 - 20, 23.06.2015
Abstract
-
Keywords
References
- Lonardi F, Coeli M, Pavanato G, Adami F, Gioga G,
- Campostrini F. Radiotherapy for non-small cell lung
- cancer in patients aged 75 and over, safety, effectiveness
- and possible impact on survival. Lung Cancer 2000; 28:
- -50.
- Tombolini V, Bonanni A, Donato V, et al. Radiotherapy
- alone in elderly patients with medically inoperable stage
- IIIA and IIIB non-small cell lung cancer. Anticancer Res
- ; 20,:4829-4833.
- Rengan R, Rosenzweig, KE, Venkatraman E, et al.
- Improved local control with higher doses of radiation in
- large-volume stage III non-small-cell lung cancer. Int J
- Radiat Oncol Biol Phys 2004;60:741-747.
- Finkelstein DM, Ettinger DS, Ruckdeschel JC. Longterm
- survivors in metastatic non-small cell lung cancer:
- an Eastern Cooperative Oncology Group Study. J Clin
- Oncol 1986;4:702–709.
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB.
- Survival determinants in extensive-stage non-small cell
- lung cancer: the Southwest Oncology Group experience.
- J Clin Oncol 1991; 9: 1618–1626.
- Borges, M., Sculier, JP., Paesmans, M., et al. Prognostic
- factors for response to chemotherapy containing
- platinum derivatives in patients with unresectable nonsmall
- cell lung cancer (NSCLC). Lung Cancer 1996;16:
- –33.
- Stanley, KE. Prognostic factors for survival in patients
- with inoperable lung cancer. J Natl Cancer Inst
- ;65:25–32.
- Hillner BE, McDonald MK, Desch CE, Smith TJ,
- Penberthy L, Retchin SM. A comparison of patterns of
- care of nonsmall cell lung carcinoma patients in a
- younger and Medigap commercially insured cohort.
- Cancer 1998;83: 1930–1937.
- Smith TJ, Penberthy L, Desch CE, et al. Differences in
- initial treatment patterns and outcomes of lung cancer in
- the elderly. Lung Cancer 1995;13:235–252.
- Jeremic B, Shibamoto Y. Pre-treatment prognostic
- factors in patients with stage III non-small cell lung
- cancer treated with hyperfractionated radiation therapy
- with or without concurrent chemotherapy. Lung Cancer
- ; 13: 21–30.
- Langer C, Hsu C, Curran D, et al. Do elderly patients
- with locally advanced non-small cell lung cancer benefit
- from combined modality therapy? A secondary analysis
- of RTOG 94-10. Int J Radiat Oncol Biol Phys 2001; 51:
- –21.
- Gauden SJ, Tripcony L. The curative treatment by
- radiation therapy alone of Stage I non- small cell lung
- cancer in a geriatric population. Lung Cancer 2001; 32:
- –79.
- Sause W, Kolesar P, Taylor SI, et al. Final results of
- phase III trial in regionally advanced unresectable nonsmall
- cell lung cancer: Radiation Therapy Oncology
- Group, Eastern Cooperative Oncology Group, and
- Southwest Oncology Group. Chest 2000; 117: 358–364.
- Newman AB, Yanez D, Harris T, et al. Weight change
- in old age and its association with mortality. J Am
- Geriatr Soc 2001; 49: 1309–1318.
- Movsas B, Scott C, Sause W, et al. The benefit of
- treatment intensification is age and histology-dependent
- in patients with locally advanced non-small cell lung
- cancer (NSCLC): a quality-adjusted survival analysis of
- radiation therapy oncology group (RTOG)
- chemoradiation studies. Int J Radiat Oncol Biol Phys
- ; 45: 1143–1149.
- Numico G, Russi E, Merlano M. Best supportive care in
- non-small cell lung cancer: Is there a role for
- radiotherapy and chemotherapy? Lung Cancer 2001; 32:
- –226.
- Chemotherapy in non-small cell lung cancer: a metaanalysis
- using updated data on individual patients from
- randomized clinical trials. Non-small Cell Lung
- Cancer Collaborative Group. BMJ 1995; 311: 899–909.
- Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of
- chemotherapy for advanced lung cancer in the elderly:
- instrumental variable and propensity analysis. J Clin
- Oncol 2001; 19: 1064–1070.
- Effects of vinorelbine on quality of life and survival of
- elderly patients with advanced non-small cell lung
- cancer. The Elderly Lung Cancer Vinorelbine Italian
- Study Group. J Natl Cancer Inst 1999; 91: 66–72.
- Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for
- elderly patients with advanced non-small cell lung
- cancer: the Multicenter Italian Lung Cancer in the
- Elderly Study (MILES) phase III randomized trial. J
- Natl Cancer Inst 2003, 95: 362–372.
- Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus
- vinorelbine versus vinorelbine alone in elderly patients
- with advanced non-small cell lung cancer. J Clin Oncol
- ; 18: 2529–2536.
- Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based
- therapy for elderly patients with advanced non-small cell
- lung cancer: implications of Eastern Cooperative
- Oncology Group 5592, a randomized trial. J Natl Cancer
- Inst 2002; 94: 173–181.
- Kelly K, Giarritta S, Akerley W, et al. Should older
- patients (Pts) receive combination chemotherapy for
- advanced stage non-small cell lung cancer (NSCLC)?
- An analysis of Southwest Oncology Trials 9509 and
- Proc Am Soc Clin Oncol 2001; 20: 329a.
- Hensing TA, Socinski MA, Schell MJ, et al. Age does
- not alter toxicity or survival for patients (pts) with stage
- IIIB/IV non-small cell lung cancer (NSCLC) treated
- with carboplatin (C) and paclitaxel (P). Proc Am Soc
- Clin Oncol 2001; 20: 346a.
- Lilenbaum RC, Herndon J, List M, et al. Single-agent
- (SA) versus combination chemotherapy (CC) in
- advanced non-small cell lung cancer (NSCLC): a
- CALGB randomized trial of efficacy, quality of life
- (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol
- ; 21: 1a.
- -
- Marmara Medical Journal 2008;21(1);011-020
- Görkem Aksu, et al.
- Radiotherapy as the primary and palliative treatment for patients aged 75 or over with locally advanced and metastatic
- Non-Small Cell Lung Cancer: Analysis of 45 cases with a review of the literature
- Kris MG, Natale RB, Herbst RS, et al. A phase II trial of
- ZD1839 (‘Iressa’) in advanced non-small cell lung
- cancer (NSCLC) patients who had failed platinum- and
- docetaxel-based regimens (IDEAL 2). Proc Am Soc
- Clin Oncol 2002; 21: 292a
- Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional
- randomized phase II trial of gefitinib for
- previously treated patients with advanced non-small cell
- lung cancer. J Clin Oncol 2003; 21: 2237–2246.
75 YAŞ VE ÜZERİ LOKAL İLERİ VE METASTATİK KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİNDE PRİMER VE PALYATİF TEDAVİ OLARAK RADYOTERAPİ UYGULAMASI: 45 VAKANIN DEĞERLENDİRİLMESİ VE LİTERATÜR İNCELEMESİ
Abstract
Amaç: Lokal ileri veya metastatik KHDAK tanılı hastalarda prognostik faktörler ve tedavi sonuçlarının değerlendirilmesi Hastalar ve Yöntem: Yetmiş beş yaş ve üzeri toplam 45 KHDAK tanılı hasta değerlendirildi. Medyan yaş 78 idi (75-93). Otuz dört hasta Evre IIIB (75%), 11 hasta (25%) ise Evre IV olarak evrelendirildi. Evre IIIB tanılı hastaların 14 tanesine (41%) küratif Radyoterapi (RT), 18 hastaya (52%) palyatif RT uygulanırken, 2 hasta (5%) sadece kemoterapi (KT) aldı.
References
- Lonardi F, Coeli M, Pavanato G, Adami F, Gioga G,
- Campostrini F. Radiotherapy for non-small cell lung
- cancer in patients aged 75 and over, safety, effectiveness
- and possible impact on survival. Lung Cancer 2000; 28:
- -50.
- Tombolini V, Bonanni A, Donato V, et al. Radiotherapy
- alone in elderly patients with medically inoperable stage
- IIIA and IIIB non-small cell lung cancer. Anticancer Res
- ; 20,:4829-4833.
- Rengan R, Rosenzweig, KE, Venkatraman E, et al.
- Improved local control with higher doses of radiation in
- large-volume stage III non-small-cell lung cancer. Int J
- Radiat Oncol Biol Phys 2004;60:741-747.
- Finkelstein DM, Ettinger DS, Ruckdeschel JC. Longterm
- survivors in metastatic non-small cell lung cancer:
- an Eastern Cooperative Oncology Group Study. J Clin
- Oncol 1986;4:702–709.
- Albain KS, Crowley JJ, LeBlanc M, Livingston RB.
- Survival determinants in extensive-stage non-small cell
- lung cancer: the Southwest Oncology Group experience.
- J Clin Oncol 1991; 9: 1618–1626.
- Borges, M., Sculier, JP., Paesmans, M., et al. Prognostic
- factors for response to chemotherapy containing
- platinum derivatives in patients with unresectable nonsmall
- cell lung cancer (NSCLC). Lung Cancer 1996;16:
- –33.
- Stanley, KE. Prognostic factors for survival in patients
- with inoperable lung cancer. J Natl Cancer Inst
- ;65:25–32.
- Hillner BE, McDonald MK, Desch CE, Smith TJ,
- Penberthy L, Retchin SM. A comparison of patterns of
- care of nonsmall cell lung carcinoma patients in a
- younger and Medigap commercially insured cohort.
- Cancer 1998;83: 1930–1937.
- Smith TJ, Penberthy L, Desch CE, et al. Differences in
- initial treatment patterns and outcomes of lung cancer in
- the elderly. Lung Cancer 1995;13:235–252.
- Jeremic B, Shibamoto Y. Pre-treatment prognostic
- factors in patients with stage III non-small cell lung
- cancer treated with hyperfractionated radiation therapy
- with or without concurrent chemotherapy. Lung Cancer
- ; 13: 21–30.
- Langer C, Hsu C, Curran D, et al. Do elderly patients
- with locally advanced non-small cell lung cancer benefit
- from combined modality therapy? A secondary analysis
- of RTOG 94-10. Int J Radiat Oncol Biol Phys 2001; 51:
- –21.
- Gauden SJ, Tripcony L. The curative treatment by
- radiation therapy alone of Stage I non- small cell lung
- cancer in a geriatric population. Lung Cancer 2001; 32:
- –79.
- Sause W, Kolesar P, Taylor SI, et al. Final results of
- phase III trial in regionally advanced unresectable nonsmall
- cell lung cancer: Radiation Therapy Oncology
- Group, Eastern Cooperative Oncology Group, and
- Southwest Oncology Group. Chest 2000; 117: 358–364.
- Newman AB, Yanez D, Harris T, et al. Weight change
- in old age and its association with mortality. J Am
- Geriatr Soc 2001; 49: 1309–1318.
- Movsas B, Scott C, Sause W, et al. The benefit of
- treatment intensification is age and histology-dependent
- in patients with locally advanced non-small cell lung
- cancer (NSCLC): a quality-adjusted survival analysis of
- radiation therapy oncology group (RTOG)
- chemoradiation studies. Int J Radiat Oncol Biol Phys
- ; 45: 1143–1149.
- Numico G, Russi E, Merlano M. Best supportive care in
- non-small cell lung cancer: Is there a role for
- radiotherapy and chemotherapy? Lung Cancer 2001; 32:
- –226.
- Chemotherapy in non-small cell lung cancer: a metaanalysis
- using updated data on individual patients from
- randomized clinical trials. Non-small Cell Lung
- Cancer Collaborative Group. BMJ 1995; 311: 899–909.
- Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of
- chemotherapy for advanced lung cancer in the elderly:
- instrumental variable and propensity analysis. J Clin
- Oncol 2001; 19: 1064–1070.
- Effects of vinorelbine on quality of life and survival of
- elderly patients with advanced non-small cell lung
- cancer. The Elderly Lung Cancer Vinorelbine Italian
- Study Group. J Natl Cancer Inst 1999; 91: 66–72.
- Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for
- elderly patients with advanced non-small cell lung
- cancer: the Multicenter Italian Lung Cancer in the
- Elderly Study (MILES) phase III randomized trial. J
- Natl Cancer Inst 2003, 95: 362–372.
- Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus
- vinorelbine versus vinorelbine alone in elderly patients
- with advanced non-small cell lung cancer. J Clin Oncol
- ; 18: 2529–2536.
- Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based
- therapy for elderly patients with advanced non-small cell
- lung cancer: implications of Eastern Cooperative
- Oncology Group 5592, a randomized trial. J Natl Cancer
- Inst 2002; 94: 173–181.
- Kelly K, Giarritta S, Akerley W, et al. Should older
- patients (Pts) receive combination chemotherapy for
- advanced stage non-small cell lung cancer (NSCLC)?
- An analysis of Southwest Oncology Trials 9509 and
- Proc Am Soc Clin Oncol 2001; 20: 329a.
- Hensing TA, Socinski MA, Schell MJ, et al. Age does
- not alter toxicity or survival for patients (pts) with stage
- IIIB/IV non-small cell lung cancer (NSCLC) treated
- with carboplatin (C) and paclitaxel (P). Proc Am Soc
- Clin Oncol 2001; 20: 346a.
- Lilenbaum RC, Herndon J, List M, et al. Single-agent
- (SA) versus combination chemotherapy (CC) in
- advanced non-small cell lung cancer (NSCLC): a
- CALGB randomized trial of efficacy, quality of life
- (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol
- ; 21: 1a.
- -
- Marmara Medical Journal 2008;21(1);011-020
- Görkem Aksu, et al.
- Radiotherapy as the primary and palliative treatment for patients aged 75 or over with locally advanced and metastatic
- Non-Small Cell Lung Cancer: Analysis of 45 cases with a review of the literature
- Kris MG, Natale RB, Herbst RS, et al. A phase II trial of
- ZD1839 (‘Iressa’) in advanced non-small cell lung
- cancer (NSCLC) patients who had failed platinum- and
- docetaxel-based regimens (IDEAL 2). Proc Am Soc
- Clin Oncol 2002; 21: 292a
- Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional
- randomized phase II trial of gefitinib for
- previously treated patients with advanced non-small cell
- lung cancer. J Clin Oncol 2003; 21: 2237–2246.
There are 126 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Authors | |
| Publication Date | June 23, 2015 |
| IZ | https://izlik.org/JA49KY88AY |
| Published in Issue | Year 2008 Volume: 21 Issue: 1 |